SCHEMBL17853571

SCHEMBL17853571

c1ccc2c(-c3nc(-c4ccc(-c5ccncc5)cc4)cc(-c4ccc(-n5c6ccccc6c6ccccc65)cc4)n3)cccc2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.43
▸ KDM4E B2RXH2 3/20 0.43
▸ ALDH1A1 P00352 2/20 0.43
▸ HPGD P15428 2/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ MAPK1 P28482 2/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ LMNA P02545 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ FLT3 P36888 3/20 0.40
▸ BMX P51813 2/20 0.40
▸ DHODH Q02127 1/20 0.39
▸ MAPK11 Q15759 2/20 0.39
▸ MAPK14 Q16539 2/20 0.39
▸ KMT2A Q03164 2/20 0.38
▸ TUBB4A P04350 1/20 0.38
▸ TUBB P07437 1/20 0.38
▸ TUBA3C P0DPH7 1/20 0.38
▸ TUBA1B P68363 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13100590 0.91 TUBB4A (0.43) MAPTKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL19397653 0.91 KDM4E (0.44) MAPTKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL13100587 0.91 TUBB4A (0.43) MAPTKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL17943442 0.91 ENPP1 (0.43) MAPTKDM4EALDH1A1HPGDMAPK1
SCHEMBL24812017 0.90 KDM4E (0.45) MAPTKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL17853592 0.90 DHODH (0.37) MAPTKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL17853570 0.89 KDM4E (0.46) MAPTKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL13100569 0.88 PIM1 (0.46) MAPTKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL17853581 0.88 DHODH (0.39) MAPTKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL15887960 0.88 FLT3 (0.41) MAPTKDM4EALDH1A1HPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160181564-A1 COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENT, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE IDEMITSU KOSAN CO., LTD. (JP) 2016-06-23 — — US disclosed
US-20160181564-A1 COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENT, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE IDEMITSU KOSAN CO., LTD. (JP) 2016-06-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160181564-A1 COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENT, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE LEF1, PIEZO1, SLC39A11 MAPT 2833/4885KDM4E 2180/4885ALDH1A1 408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback